6-K: Report of foreign private issuer (related to financial reporting)
Hutchmed (China) (00013.HK) plans to hold a board of directors meeting on July 31 to approve its mid-term performance.
Hutchmed (China) (00013.HK) announced on June 26th that the company will hold a board meeting on Wednesday, July 31st, 2024 to approve the mid-term performance of the company and its subsidiaries for the six months ending on June 30th, 2024 (including) and release it at 7:00 pm that day (Hong Kong time).
HUTCHMED: DATE OF BOARD MEETING AND ANNOUNCEMENT OF 2024 INTERIM RESULTS
Express News | HUTCHMED to Announce 2024 Half-Year Financial Results
Goldman Sachs Maintains Hutchmed (China)(HCM.US) With Hold Rating
Goldman Sachs analyst Paul Choi maintains $Hutchmed (China)(HCM.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 48.0% and a total average return of 4.5% over the
Takeda's Cancer Drug Gets European Commission Approval
Japan's Takeda (TYO:4502) received approval from the European Commission for its metastatic colorectal cancer (CRC) drug FRUZAQLA as a monotherapy indicated for treating adult patients, its partner, H
GF Sec: Rated Hutchmed (China) as a "buy", with a target price of HKD 41.16.
GF Securities expects Hutchmed (China) to have a net income attributable to shareholders of -$116 million, $100 million, and $116 million for the years 2024-2026, respectively.
[Brokerage Focus] East Money Information Securities maintains a buy rating for Hutchmed (China) (00013), citing a large unmet need for colorectal cancer.
King Wuzi News | Dongfang Fortune Securities Research Institute recently announced that hutchmed (china) cooperated with partner Takeda (TSE: 4502 / NYSE: TAK) to obtain the approval of the European Commission to use FRUZAQLA (furquini) as a monotherapy for the treatment of past Standard treatments, including fluoropyrimidine-based chemotherapy, oxaliplatin, and irinotecan, VEGF treatment and EGFR treatment, as well as capecitabine, temozolomide or regorafenib.
Hutchmed (China) (00013) will introduce the latest research and development progress on July 9th.
Hutchmed (China) Limited announced today in a statement that it will launch in 2024...
Fruquintinib's European stock price fell more than 20%, Hutchmed (China)'s stock price rise failed as a wind vane?
The key trends of Fruquintinib are gradually becoming a market investment and a direction indicator for hutchmed (china). However, sometimes the direction indicator may not react in time.
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment
Biopharmaceutical company Hutchmed (China) (HCM.L, H7T2.F) and its partner Takeda (TKD.F) received European Commission approval for Fruzaqla. The treatment is meant for adult patients with metastatic
Brokerage Focus: Huayuan Securities maintains a 'buy' rating on hutchmed (china) (00013), indicating that there will be intensive future catalytic events and the innovative pipeline will enter the harvest period.
Jingu Caixun | According to Huayuan Securities, Hutchmed (China) (00013) announced on June 22 that Takeda has obtained approval from the European Commission for FRUZAQLA (fugui tinib) to be listed. The monotherapy is used to treat adult patients with metastatic colorectal cancer who have progressed or are intolerant to disease after treatment with fluoropyrimidine-based, oxaliplatin-based, and irinotecan-based chemotherapies, anti-vascular endothelial growth factor (VEGF) therapy, and anti-epidermal growth factor receptor (EGFR) therapy, becoming the first approved for use in the European Union in more than ten years.
Express News | HUTCHMED China Ltd - European Commission Approval for Fruzaqla
Hutchmed (China) (00013.HK): Takeda gains approval from European Commission for FRUZAQLA (fugquintinib).
On June 24th, Gralon Healthcare announced that its partner Takeda (TSE: 4502/NYSE: TAK) has received approval from the European Commission for FRUZAQLA (fruquintinib) as a single-agent therapy for the treatment of previously treated patients with fluoropyrimidine-containing, oxaliplatin-containing, and irinotecan-containing regimens.
Hutchmed (China) announced Takeda's approval of FRUZAQLA (furquaretinib) by the European Commission.
- Based on the positive results of the FRESCO-2 global phase III clinical trial, FRUQUINTINIB (famitinib) has been approved for the treatment of refractory metastatic colorectal cancer - FRUQUINTINIB (famitinib) is the first innovative targeted therapy approved for the treatment of metastatic colorectal cancer in the European Union for more than a decade, regardless of the patient's biomarker status - Hong Kong, Shanghai and Florham Park, New Jersey, June 22, 2024 / PRNewswire / -- Hutchmed (China) Limited ("Hutchmed" or "HU")
Takeda Gets EU Approval for Fruzaqla for Colorectal Cancer
Express News | HUTCHMED (China) Ltd -
Express News | HUTCHMED Announces European Commission Approval for Fruzaqla® (Fruquintinib) Received by Takeda
Express News | Reported Earlier, HUTCHMED Publishes Phase III Sovleplenib Results, 48.4% Response Rate In ITP Patients Versus 0% In Placebo Group
Express News | - HUTCHMED China Ltd - Lancet Publish Phase III Eslim-01 Results